ERBB2 and breast carcinoma: It has been reported that lapatinib, in addition to inducing apoptosis in HER2-positive breast cancer cells, also increased the sensitivity of these cells to radiation and restored tamoxifen sensitivity in tamoxifen-resistant breast cancer models (10).